6 months ago
Legend Biotech Carvykti®, a Breakthrough CAR-T Cell Therapy Latest news from Carvykti Carvykti® (cilta-cel, Ciltacabtagene Autoleucel) is the first CAR-T cell therapy to receive a positive opinion ...
6 months ago
AACR 2024/Breakthrough Chinese Research – Monotherapy for Late-stage #SolidTumors and #Lymphomas AACR2024 #AACR2024 At the 2024 American Association for Cancer Research (#AACR) Annual Meeti...
6 months ago
AACR 2024/Breakthrough in Treating Recurrent or Metastatic Nasopharyngeal Carcinoma by Chinese Medical Team AACR 2024 We’re thrilled to share groundbreaking updates from the 2024 Ameri...
6 months ago
Bluebird bio Abecma: A Revolutionary CAR-T Cell Therapy for Multiple Myeloma Introduction Multiple myeloma is a devastating form of blood cancer that affects plasma cells, a type of white blood cel...
6 months ago
Abecma Bristol Myers Squibb’s Revolutionary CAR-T Cell Immunotherapy Introduction Abecma (idecabtagene vicleucel) is a groundbreaking chimeric antigen receptor (CAR) T-cell therapy developed ...
6 months ago
Brief Introduction of Abecma for Multiple Myeloma Multiple myeloma is a devastating blood cancer that affects plasma cells, a type of white blood cell responsible for producing antibodies. Traditio...
6 months ago
FDA Approves BMS’s Abecma (Idecabtagene Vicleucel) for Relapsed or Refractory Multiple Myeloma Abecma (idecabtagene vicleucel) is the first approved CAR-T cell immunotherapy for relapsed or r...
6 months ago
BCMA CAR-T Approval, Efficacy Comparison of Four RRMM CAR-T Between China and the United States The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was recen...
6 months ago
Abecma is a BCMA-targeted CAR-T cell therapy Abecma is a BCMA CAR-T therapy Abecma is a first-in-class, BCMA-directed, personalized immune cell therapy. BCMA is a protein that is nearly universally...
6 months ago
Abecma Clinical Trial Data Abecma is a CAR-T cell immunotherapy targeting BCMA, which is expressed on the surface of multiple myeloma cells. Abecma can recognize and bind to BCMA, leading to the pr...
6 months ago
Recent Updates on CAR-T Clinical Trials for Multiple Myeloma Multiple myeloma is a blood cancer where plasma cells proliferate in an uncontrolled manner. Patients with this incurable cancer exhibit...
6 months ago
Bluebird CAR-T Multiple Myeloma Abecma is the world’s first approved BCMA-targeted CAR-T cell therapy, co-developed by Bristol Myers Squibb (BMS) and Bluebird Bio. It is a first-in-class, BCM...
By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
© Copyright 2023 Advanced Medicine In China. All rights reserved.
